



SUBSTITUTE CLAIMS

1. An anti-craving medication for administration to the body of an individual suffering from substance abuse, said medication comprising: i) a first component comprising of the following agents: selected forms of selected amino-acids, ii) a second component comprising of the following agents: selected forms of selected vitamins, and iii) a third component comprising of the following agents: selected forms of selected minerals, said agents being selected for their combined ability to reduce craving, and said agents further being selected so as to allow efficient use of the medication by such body of an individual suffering from substance abuse.
2. The anti-craving medication of claim 1, wherein said selection of said agents so as to allow efficient use of the medication by the body of an individual suffering from substance abuse further comprises: selection based upon said agents' combined ability to promote crossing of the blood/brain baffle by at least one of said agents.
3. The anti-craving medication of claim 1, wherein said selection of said agents so as to allow efficient use of the medication by the body of an individual suffering from substance abuse further comprises: selection based upon said agents' abilities to promote liver by-pass by at least one of said agents.
4. The anti-craving medication of claim 1, wherein said selection of said agents so as to allow efficient use of the medication by the body of an individual suffering from

substance abuse further comprises: selection based upon said agents' abilities to promote stomach lining by-pass by at least one of said agents.

5. The anti-craving medication of claim 1, wherein said selection of said agents so as to allow efficient use of the medication by the body of an individual suffering from substance abuse further comprises: selection based upon said agents' combined ability to promote intestinal lining by-pass by at least one of said agents.
6. The anti-craving medication of claim 1, wherein said selection of said agents so as to allow efficient use of the medication by the body of an individual suffering from substance abuse further comprises: selection based upon said agents' combined ability to promote,
 - i) crossing of the blood/brain barrier by at least one of said agents,
 - ii) liver by-pass by at least one of said agents,
 - iii) stomach lining by-pass by at least one of said agents, and
 - iv) intestinal lining by-pass by at least one of said agents.
7. The anti-craving medication of claim 1, wherein said selection of forms of selected amino acids further comprises: preferentially selecting forms of said selected amino-acids which easily cross the blood/brain baffle.
8. The anti-craving medication of claim 7, wherein said selection of forms of selected amino acids further comprises: preferentially selecting isomers of said selected amino-acids

having the ability to easily cross the blood/brain barrier.

9. The anti-craving medication of claim 1, wherein said first component further comprises:
at least three ~~four~~ amino-acids ~~selected from the group consisting of: D-phenylalanine, L-phenylalanine, L-tyrosine, L-tryptophan and L-glutathione.~~
10. The anti-craving medication of claim 1, wherein said selection of said forms of said minerals further comprises: selecting molecular forms of the minerals having small size.
11. The anti-craving medication of claim 1, wherein said selection of said forms of said minerals further comprises: selecting mineral forms which are water soluble.
12. The anti-craving medication of claim 1, wherein said selection of said forms of said minerals further comprises: selecting mineral forms which are cellularly active.
13. The anti-craving medication of claim 1, wherein said selection of said forms of said minerals further comprises: selectively avoiding usage of forms of said minerals which release calcium while being metabolized, whereby efficient use of the medication by such body of an individual suffering from substance abuse is promoted.
14. The anti-craving medication of claim 1, wherein said selection of said forms of said minerals further comprises: selecting minerals in sulfate forms.

15. The anti-craving medication of claim 1, wherein said selection of said forms of said minerals further comprises: selecting non-chelate mineral forms.
16. The anti-craving medication of claim 1, wherein said third component further comprises: at least four minerals. ~~five members selected from the group consisting of: magnesium chloride, zinc sulfate, cupric sulfate, manganese sulfate, chromic chloride, sodium selenite.~~
17. The anti-craving medication of claim 1, wherein said agents selected so as to allow efficient use of the medication by the body of an individual suffering from substance abuse further comprises: selecting vitamin forms which are water soluble.
18. The anti-craving medication of claim 1, wherein said agents selected so as to allow efficient use of the medication by the body of an individual suffering from substance abuse further comprises: selecting vitamin forms which are cellularly active.
19. The anti-craving medication of claim 1, wherein said second component further comprises: riboflavin-S-phosphate sodium, whereby efficient use of the medication by such body of an individual suffering from substance abuse is promoted.
20. The anti-craving medication of claim 1, wherein said third component further comprises: methylcobolamin, whereby efficient use of the medication by such body of an individual suffering from substance abuse is promoted.

21. The anti-craving medication of claim 1, wherein said third component further comprises:
at least three vitamins, ~~four members selected from the group consisting of: folic acid sodium salt, methylcobolamin, beet-source ascorbic acid sodium salt, thiamine hydrochloride, pyridoxal-5-phosphate monohydrate, riboflavin-5-phosphate sodium, niacinamide, dexpantenol, and inositol.~~
22. The anti-craving medication of claim 1, wherein said selection of said agents of said first component further comprises: selecting said agents so as to allow said first component to be a single vial of medication suitable for intravenous administration.
23. The anti-craving medication of claim 1, wherein said selection of said agents of said second component further comprises: selecting said agents so as to allow said second component to be a single vial of medication suitable for intravenous administration.
24. The anti-craving medication of claim 1, wherein said selection of said agents of said third component further comprises: selecting said agents so as to allow said third component to be a single vial of medication suitable for intravenous administration.
25. The anti-craving medication of claim 1, wherein said selection of said agents of each of said first, second and third components further comprises: selecting said agents so as to allow each of said first, second and third components to be a single vial of medication suitable for intravenous administration, whereby a total of only three vials must be administered to such patient suffering from substance abuse.

26. The anti-craving medication of claim 25, wherein each of said components is introduced into a saline solution.
27. The anti-craving medication of claim 26, wherein said saline solution is adjusted to maintain an osmolarity in the range between approximately 210 mOsm/l and approximately 300 mOsm/l, preferably approximately 295 mOsm/l.
28. (Withdrawn)
29. An anti-craving medication for administration to the body of an individual suffering from substance abuse, said medication comprising: i) a first component comprising of the following agents: selected forms of selected amino-acids, ii) a second component comprising of the following agents: selected forms of selected vitamins, and iii) a third component comprising of the following agents: selected forms of selected minerals, said agents being selected for their combined ability to reduce craving, and said agents further being selected so as to require minimal metabolic processing of said agents by such body of individual suffering from substance abuse prior to the agents taking effect in the brain of such individual.
30. (Withdrawn)
31. (Withdrawn)
32. (Withdrawn)
33. (Withdrawn)

34. (Withdrawn)

35. (Withdrawn)

36. (Withdrawn)

37. (Withdrawn)

38. (Withdrawn)

39. (Withdrawn)